As the Head CMC & Industrialization, PS Biotech & CGT unit at Bayer Pharmaceuticals, Dirk Böhm leads and coaches a cross-functional team responsible for process development, quality, manufacturing, and regulatory aspects of cell and gene therapy products. He has over 20 years of experience in international biotech and pharma manufacturing settings, with a strong track record of delivering excellent results efficiently and reliably to high quality standards.
His mission is to bring innovative therapies to patients through collaboration and excellence in execution across the Bayer CGT companies and the units in the Bayer group. He is passionate about building efficient teams and organizations, developing talent, and creating a motivating environment. He is also focused on continuous improvement and a clear strategy and direction to bring the best performance year over year. He is an innovation ambassador of the organization, supporting and enabling scouting of external technology and business opportunities.
Panel Discussion
Monday, September 22
06:10 pm - 06:55 pm
Live in Berlin
Less Details
As pharmaceutical manufacturers face rising cost pressures, supply chain disruptions, and increasing demands for efficiency, the industry must rethink its approach to operational excellence. A holistic strategy—one that integrates innovative business models, digitalization, and resilient supply chains—is essential to navigating these challenges. From supply chain resilience in an era of geopolitical uncertainty to the role of new ownership models like Dynamic Shared Ownership (DSO), panelists will discuss how companies can optimize efficiency while remaining agile and competitive. In this session, you will learn more about: